Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan R Targan

Showing results (141-150 of 189) with videos related to

Pageof 19
Sort By:
Gastroenterology|April 17, 2012
Abatacept for Crohn's disease and ulcerative colitisWilliam J Sandborn, Jean-Frederic Colombel, Bruce E Sands, et al.
Scientific Reports|October 24, 2020
Direct signaling of TL1A-DR3 on fibroblasts induces intestinal fibrosis in vivoNoam Jacob, Kotaro Kumagai, Jay P Abraham, et al.
Inflammatory Bowel Diseases|April 23, 2016
TNFRSF1B Is Associated with ANCA in IBDDalin Li, Mark S Silverberg, Talin Haritunians, et al.
Inflammatory Bowel Diseases|March 11, 2011
Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behaviorGary R Lichtenstein, Stephan R Targan, Marla C Dubinsky, et al.
Inflammatory Bowel Diseases|March 4, 2016
Perianal Crohn's Disease is Associated with Distal Colonic Disease, Stricturing Disease Behavior, IBD-Associated Serologies and Genetic Variation in the JAK-STAT PathwayManreet Kaur, Deepa Panikkath, Xiaofei Yan, et al.
Gastroenterology|May 9, 2007
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE TrialStephan R Targan, Brian G Feagan, Richard N Fedorak, et al.
Inflammatory Bowel Diseases|June 8, 2017
Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBDSoon Man Yoon, Talin Haritunians, Sultan Chhina, et al.
Frontiers in Immunology|July 11, 2022
BATF3 Protects Against Metabolic Syndrome and Maintains Intestinal Epithelial HomeostasisHussein Hamade, Jasmine T Stamps, Dalton T Stamps, et al.
The American Journal of Gastroenterology|December 1, 2007
Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and predictionPeggy Vandewalle-El Khoury, Jean-Frederic Colombel, Sofie Joossens, et al.
Journal of Clinical Gastroenterology|December 13, 2005
Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's diseaseMaria T Abreu, Jordan L Geller, Eric A Vasiliauskas, et al.
Pageof 19

Showing results (141-150 of 189) with videos related to

Sort By:
Pageof 19
Gastroenterology|April 17, 2012
Abatacept for Crohn's disease and ulcerative colitisWilliam J Sandborn, Jean-Frederic Colombel, Bruce E Sands, et al.
Scientific Reports|October 24, 2020
Direct signaling of TL1A-DR3 on fibroblasts induces intestinal fibrosis in vivoNoam Jacob, Kotaro Kumagai, Jay P Abraham, et al.
Inflammatory Bowel Diseases|April 23, 2016
TNFRSF1B Is Associated with ANCA in IBDDalin Li, Mark S Silverberg, Talin Haritunians, et al.
Inflammatory Bowel Diseases|March 11, 2011
Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behaviorGary R Lichtenstein, Stephan R Targan, Marla C Dubinsky, et al.
Inflammatory Bowel Diseases|March 4, 2016
Perianal Crohn's Disease is Associated with Distal Colonic Disease, Stricturing Disease Behavior, IBD-Associated Serologies and Genetic Variation in the JAK-STAT PathwayManreet Kaur, Deepa Panikkath, Xiaofei Yan, et al.
Gastroenterology|May 9, 2007
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE TrialStephan R Targan, Brian G Feagan, Richard N Fedorak, et al.
Inflammatory Bowel Diseases|June 8, 2017
Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBDSoon Man Yoon, Talin Haritunians, Sultan Chhina, et al.
Frontiers in Immunology|July 11, 2022
BATF3 Protects Against Metabolic Syndrome and Maintains Intestinal Epithelial HomeostasisHussein Hamade, Jasmine T Stamps, Dalton T Stamps, et al.
The American Journal of Gastroenterology|December 1, 2007
Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and predictionPeggy Vandewalle-El Khoury, Jean-Frederic Colombel, Sofie Joossens, et al.
Journal of Clinical Gastroenterology|December 13, 2005
Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's diseaseMaria T Abreu, Jordan L Geller, Eric A Vasiliauskas, et al.
Pageof 19